An update on gemcitabine, rituximab, and oxaliplatin in combination for relapsed/refractory non-Hodgkin lymphomas.

Robert M. Crescentini,Kendra L. Sweet,Jijun Liu,Idalia Liboy,Samir Dalia,Julio C. Chavez,Celeste M. Bello,Lubomir Sokol,Eduardo M. Sotomayor,Fernando Cabanillas,Jennifer L. Cultrera

An update on gemcitabine, rituximab, and oxaliplatin in combination for relapsed/refractory non-Hodgkin lymphomas.

2017

Robert M. Crescentini
Kendra L. Sweet
Jijun Liu
Idalia Liboy
Samir Dalia
Julio C. Chavez
Celeste M. Bello
Lubomir Sokol
Eduardo M. Sotomayor
Fernando Cabanillas
Jennifer L. Cultrera

8084 Background: Relapsed/refractory non-Hodgkin lymphomas (NHL) have no standard of care. A variety of salvage chemotherapy options are available. We previously reported results of our phase II tr...

Keywords:

Pathology
Rituximab
Oxaliplatin
Oncology
Gemcitabine
Refractory
Medicine
Chemotherapy
Internal medicine
salvage treatment
standard of care
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations